TY  - JOUR
AU  - Liu, Yibin
AU  - Keib, Anna
AU  - Neuber, Brigitte
AU  - Wang, Lei
AU  - Riemer, Angelika
AU  - Bonsack, Maria
AU  - Hückelhoven-Krauss, Angela
AU  - Schmitt, Anita
AU  - Müller-Tidow, Carsten
AU  - Schmitt, Michael
TI  - Definition and Characterization of SOX11-Derived T Cell Epitopes towards Immunotherapy of Glioma.
JO  - International journal of molecular sciences
VL  - 24
IS  - 3
SN  - 1422-0067
CY  - Basel
PB  - Molecular Diversity Preservation International
M1  - DKFZ-2023-00333
SP  - 1943
PY  - 2023
AB  - The transcription factor SOX11 is a tumor-associated antigen with low expression in normal cells, but overexpression in glioblastoma (GBM). So far, conventional surgery, chemotherapy, and radiotherapy have not substantially improved the dismal prognosis of relapsed/refractory GBM patients. Immunotherapy is considered a promising strategy against GBM, but there is a fervent need for better immunotargets in GBM. To this end, we performed an in silico prediction study on SOX11, which primarily yielded ten promising HLA-A*0201-restricted peptides derived from SOX11. We defined a novel peptide FMACSPVAL, which had the highest score according to in silico prediction (6.02 nM by NetMHC-4.0) and showed an exquisite binding affinity to the HLA-A*0201 molecule in the peptide-binding assays. In the IFN-γ ELISPOT assays, FMACSPVAL demonstrated a high efficiency for generating SOX11-specific CD8+ T cells. Nine out of thirty-two healthy donors showed a positive response to SOX11, as assessed by the ELISPOT assays. Therefore, this novel antigen peptide epitope seems to be promising as a target for T cell-based immunotherapy in GBM. The adoptive transfer of in vitro elicited SOX11-specific CD8+ T cells constitutes a potential approach for the treatment of GBM patients.
KW  - HLA-A*0201 (Other)
KW  - SOX11 (Other)
KW  - glioma (Other)
KW  - immunotherapy (Other)
KW  - tumor-associated antigen (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36768267
DO  - DOI:10.3390/ijms24031943
UR  - https://inrepo02.dkfz.de/record/267555
ER  -